Health News Us

Pfizer COVID-19 vaccine works well in big real world test

A real-world test of Pfizer’s COVID-19 vaccine in more than half a million people confirms that it’s very effective at preventing serious illness or death, even after one dose.

Pfizer’s vaccine
A pharmacist prepares a syringe with Pfizer’s vaccine at a COVID-19 vaccination site in New York. A real-world test of Pfizer’s COVID-19 vaccine in more than half a million people has confirmed it’s highly effective at preventing serious illness or death, even after one dose, according to a report released on Wednesday, Feb. 24, 2021. (AP Photo/Mary Altaffer)

Wednesday’s published results, from a mass vaccination campaign in Israel, give strong reassurance that the benefits seen in smaller, limited testing persisted when the vaccine was used much more widely in a general population with various ages and health conditions.

The vaccine was 92% effective at preventing severe disease after two shots and 62% after one. Its estimated effectiveness for preventing death was 72% two to three weeks after the first shot, a rate that may improve as immunity builds over time.

It seemed as effective in folks over 70 as in younger people.

This is immensely reassuring … better than I would have guessed, said the Mayo Clinic’s Dr. Gregory Poland.

Vanderbilt University’s Dr. Buddy Creech agreed: Even after one dose we can see very high effectiveness in prevention of death, he said.

Neither doctor had a role in the Israel study but both are involved in other coronavirus vaccine work.

Both doctors also said the new results may boost consideration of delaying the second shot, as the United Kingdom is trying, or giving one dose instead of two to people who have already had COVID-19, as France is doing, to stretch limited supplies.

I would rather see 100 million people have one dose than to see 50 million people have two doses, Creech said. I see a lot of encouragement on one dose in the results from Israel, which were published by the New England Journal of Medicine.

The vaccine, made by Pfizer and its German partner BioNTech, is given as two shots, three weeks apart, in most countries.

The study was led by researchers from the Clalit Research Institute and Ben-Gurion University of the Negev in Israel, with Harvard University in the U.S. It did not report on safety of the vaccine, just effectiveness, but no unexpected problems arose in previous testing.

Researchers compared nearly 600,000 people 16 and older in Israel’s largest health care organization who were given shots in December or January to an equal number of people of similar age, sex and health who did not receive vaccine. None of the participants had previously tested positive for the virus.

The vaccine was estimated to be 57% effective at preventing any symptoms of COVID-19 two to three weeks after the first dose, and 94% a week or more after the second dose.

Effectiveness was 74% after one shot and 87% after two for preventing hospitalization, and 46% and 92% for preventing confirmed infection. Reducing infections gives hope that the vaccine may curb spread of the virus, but this type of study can’t determine if that’s the case.

Read full article on Associated Press

Print Friendly, PDF & Email

We Recommend

The yoopya.com portal presents worldwide news, covering a large spectrum of content categories including Entertainment, Politics, Sports, Health, Education, Science and Technology and more. Top local and global news in the best possible journalistic quality. We connect users via a free webmail service and innovative.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Pfizer COVID-19 vaccine works well in big real world test